Volume 14 Supplement 1
6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Meeting abstracts
Edited by John C Burnett Jr, Franz Hofmann, Kazuwa Nakao, Harald HHW Schmidt and Johannes-Peter Stasch
Publication of this supplement has been fully funded by Bayer Pharma AG. Johannes-Peter Stasch is an employee of Bayer Pharma AG, Wuppertal, Germany. He holds many patents on sGC stimulators and sGC activators. John C Burnett Jr is the chairman of the advisory board for Nile Therapeutics and is a Co-Founder and the Chief Scientific Officer for Zumbro Discovery. Mayo Clinic has licensed CD-NP to Nile Therapeutics and MANP to Zumbro Discovery. The other Supplement Editors declare that they have no competing interests.
6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications. Go to conference site.
Erfurt, Germany28-30 June 2013
Page 3 of 3
-
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P63
-
Endothelial dysfunction in a mouse model of human neutral lipid storage disease
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P64 -
Discovery of neuroprotective soluble guanylate cyclase modulators (GCMs) aciting via NO/GC/cGMP/CREB pathway
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P65 -
Genetic silencing of sGC β1 in cancer: role of epigenetic regulation
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P66 -
Krait natriuretic peptide (KNP): a non-classical NP
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P67 -
Cardiac cGMP/cGMP-dependent protein kinase I signalling requires cysteine-rich LIM-only protein 4 (CRP4) to oppose angiotensin II induced hypertrophy and fibrosis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P68 -
Differential regulation of platelet inhibition by cGMP- and cAMP-dependent protein kinases
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P69 -
Linaclotide induces secretion of cGMP from mouse colonic epithelium
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P70 -
Receptor guanylyl cyclase B-mediated cGMP signalling controls axon bifurcation of cranial sensory ganglion neurons at the embryonic hindbrain
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P71 -
NO/cGMP/pCREB re-activation reverses cognition deficits and attenuates amyloid-β neuropathology in transgenic models of Alzheimer’s disease
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P72 -
Endothelial GC-A can be a therapeutic target for metabolic syndrome
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P73 -
Phospho-specific antisera to monitor N-terminal autophosphorylation of cGMP-dependent protein kinase type I
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P74 -
The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P75 -
Analysis of cGMP signalling with transgenic mice expressing FRET-based cGMP sensors
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P76 -
Genes involved in pulmonary hypertension of mice with endothelial-specific ablation of guanylyl cyclase A
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P77 -
Identification of cCMP binding and activated proteins
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P78 -
Activation profile of cGMP-dependent protein kinase Iα
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P79 -
Anti-interleukin-6 therapy for treatment of high platelet counts in cGMP-dependent protein kinase I gene-targeted mice
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P80
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 2.8
5-year Journal Impact Factor: 2.8
Source Normalized Impact per Paper (SNIP): 0.774
SCImago Journal Rank (SJR): 0.710
Speed 2023
Submission to first editorial decision (median days): 25
Submission to acceptance (median days): 178
Usage 2023
Downloads: 790,731
Altmetric mentions: 400
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication